ASO GROUP Ltd Purchases New Stake in Zoetis Inc. $ZTS

ASO GROUP Ltd purchased a new stake in Zoetis Inc. (NYSE:ZTS) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 71,884 shares of the company’s stock, valued at approximately $9,044,000. Zoetis makes up about 3.5% of ASO GROUP Ltd’s investment portfolio, making the stock its 4th biggest holding.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Miller Financial Services LLC raised its stake in Zoetis by 73.3% during the fourth quarter. Miller Financial Services LLC now owns 2,523 shares of the company’s stock worth $317,000 after acquiring an additional 1,067 shares in the last quarter. Compass Capital Management Inc. raised its stake in Zoetis by 28.1% during the fourth quarter. Compass Capital Management Inc. now owns 62,582 shares of the company’s stock worth $7,874,000 after acquiring an additional 13,734 shares in the last quarter. ICICI Prudential Asset Management Co Ltd acquired a new position in Zoetis during the fourth quarter worth about $3,649,000. Meiji Yasuda America Inc acquired a new position in Zoetis during the fourth quarter worth about $1,449,000. Finally, Hikari Tsushin Inc. raised its stake in Zoetis by 295.8% during the fourth quarter. Hikari Tsushin Inc. now owns 164,238 shares of the company’s stock worth $20,664,000 after acquiring an additional 122,744 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Rosen, Bronstein Gewirtz & Grossman, the Schall Law Firm, DJS Law Group, and others, urged investors to join or lead a class action against Zoetis, keeping litigation risk in focus and potentially weighing on sentiment. Article Title
• Negative Sentiment: The lawsuits allege Zoetis misled investors about weakening veterinarian adoption and prescription trends, which could raise concerns about the company’s underlying growth outlook and create overhang on the stock. Article Title
• Neutral Sentiment: Rosen Law Firm and others reminded shareholders that July 27, 2026 is the lead-plaintiff deadline, but these notices are procedural and do not change Zoetis’ fundamentals by themselves. Article Title
• Neutral Sentiment: Bank of America Securities reportedly maintained a “Hold” rating on Zoetis, which suggests Wall Street remains cautious but not overtly bearish. Article Title

Insider Activity at Zoetis

In related news, Director Paul Bisaro bought 2,000 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the acquisition, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Michael B. Mccallister bought 3,000 shares of Zoetis stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the acquisition, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 11,650 shares of company stock worth $886,384 over the last ninety days. Insiders own 0.22% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on ZTS shares. William Blair reissued an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. UBS Group lowered their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Argus reissued a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Finally, Stifel Nicolaus lowered their price objective on Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a research note on Friday, May 22nd. Six analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Zoetis currently has an average rating of “Hold” and a consensus price target of $133.92.

Zoetis Stock Performance

Zoetis stock opened at $81.51 on Friday. The business has a 50 day moving average of $97.70 and a 200-day moving average of $114.47. Zoetis Inc. has a 1 year low of $72.38 and a 1 year high of $168.83. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The company has a market capitalization of $34.17 billion, a P/E ratio of 13.52, a P/E/G ratio of 1.27 and a beta of 0.75.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter in the previous year, the company earned $1.48 earnings per share. The business’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.6%. Zoetis’s dividend payout ratio is presently 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.